作者
Selina M Luger, Zhuoxin Sun, Ryan J Mattison, Elisabeth Paietta, Kathryn G Roberts, Yanming Zhang, Janis Racevckis, Hillard M Lazarus, Jacob M Rowe, Daniel A Arber, Matthew J Wieduwilt, Michaela Liedtke, Julie Bergeron, Brent L Wood, Yaqi Zhao, Gang Wu, Ti-Cheng Chang, Wenchao Zhang, Keith W Pratz, Shira N Dinner, Noelle V Frey, Steven D Gore, Bhavana Bhatnagar, Ehab L Atallah, Geoffrey L Uy, Deepa Jeyakumar, Tara L Lin, Cheryl L Willman, Daniel J DeAngelo, Elad Sharon, Richard F Little, Harry P Erba, Richard M Stone, Charles G Mullighan, Mark R Litzow, Martin S Tallman
发表日期
2023/11/28
期刊
Blood
卷号
142
页码范围
2877
出版商
Content Repository Only!
简介
Introduction: ECOG ACRIN E1910 is a randomized phase III trial that showed that adults with newly diagnosed BCR::ABL1 negative acute lymphoblastic leukemia (ALL) who become MRD negative (<0.01%) after induction chemo who receive blinatumomab with conventional chemotherapy (chemo) have improved survival compared with those who received chemo only (Litzow et al, Blood (2022) 140: Supplement 2, LBA-1). However, not all pts were able to receive all four planned cycles of blinatumomab in consolidation. In this report we assessed outcomes of pts in the blinatumomab arm of the trial who received all 4 cycles of blinatumomab compared to those who received 1-2 cycles.
Methods: Patient between the ages of 30 and 70 with newly diagnosed BCR::ABL1 negative B-lineage ALL were enrolled and initially received 2.5 months of combination induction chemo utilizing a BFM-like regimen adapted from …
学术搜索中的文章
SM Luger, Z Sun, RJ Mattison, E Paietta, KG Roberts… - Blood, 2023